Axsome Therapeutics (AXSM) Receives $19.50 Consensus Price Target from Brokerages

Shares of Axsome Therapeutics (NASDAQ:AXSM) have earned an average rating of “Hold” from the six research firms that are covering the company, MarketBeat reports. Two analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $19.50.

A number of research firms recently weighed in on AXSM. ValuEngine upgraded Axsome Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Zacks Investment Research downgraded Axsome Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, March 13th.

Shares of AXSM remained flat at $$2.55 during trading hours on Thursday. The stock had a trading volume of 163,392 shares, compared to its average volume of 141,457. The company has a market cap of $65.01, a P/E ratio of -2.06 and a beta of -0.16. The company has a current ratio of 2.90, a quick ratio of 2.90 and a debt-to-equity ratio of 0.40. Axsome Therapeutics has a 12-month low of $2.05 and a 12-month high of $6.45.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Wednesday, March 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.04. equities research analysts expect that Axsome Therapeutics will post -0.26 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in AXSM. JPMorgan Chase & Co. lifted its position in Axsome Therapeutics by 1.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,459,117 shares of the company’s stock worth $8,026,000 after buying an additional 23,229 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Axsome Therapeutics in the 4th quarter worth approximately $271,000. Finally, Goldman Sachs Group Inc. purchased a new position in Axsome Therapeutics in the 4th quarter worth approximately $238,000. Institutional investors own 22.84% of the company’s stock.

WARNING: “Axsome Therapeutics (AXSM) Receives $19.50 Consensus Price Target from Brokerages” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at

About Axsome Therapeutics

Axsome Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system (CNS) disorders. The company's product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and Alzheimer's disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes.

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit